Navigating the Path to Transplant: HSCT and Supportive Care in SDS

For many families living with Shwachman-Diamond Syndrome (SDS), the possibility of a Hematopoietic Stem Cell Transplant (HSCT) is a major milestone in the care journey. A transplant is an important and potentially curative treatment for the life-threatening blood problems associated with the condition ^[1]. However, a transplant is a significant undertaking that carries severe risks and requires careful timing, individualized indications, and a specialized medical team. Stable blood counts or the diagnosis alone do not automatically justify transplant.

The Timing “Window”: Why Context Matters

The single most important factor in the success of an SDS transplant is the reason it is being performed. Research from historical cohorts shows a dramatic difference in survival rates based on whether the transplant happens before or after the marrow has turned into cancer ^[2][3]. (Note: These statistics represent specific past cohorts and methods, not predictions for your child’s individual future).

• Bone Marrow Failure: When a transplant is done because the marrow is failing to make enough healthy cells, the outcomes are generally more favorable. Studies show survival rates for these patients in specific cohorts were approximately 72% to 80% ^[2][3].
• MDS and AML: If the transplant happens after a child develops advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML), the outcomes become much more difficult. Survival for MDS in these cohorts was around 49%, and for AML, it was as low as 9% ^[2].

This is why your care team emphasizes surveillance—the goal is to identify indications early ^[4][5].

Reduced Intensity Conditioning (RIC)

Before receiving new stem cells, a patient must undergo “conditioning”—a process using chemotherapy or radiation to clear out the old marrow. In SDS, a specialized approach called Reduced Intensity Conditioning (RIC) is often considered ^[4].

• Lower Toxicity: Because SDS affects the whole body, the organs (like the liver and lungs) can be more sensitive to high-dose chemotherapy ^[4]. RIC aims to use lower doses to achieve the goal while reducing the risk of severe organ damage, though it still carries major toxicity and graft-failure considerations ^[4].
• Radiation Trade-offs: Expert consensus often recommends considering avoiding or limiting Total Body Irradiation (TBI) in SDS patients, as radiation can further impact growth and increase the risk of secondary cancers later in life. However, whether TBI can be avoided completely depends on the specific clinical situation ^[4][6].

Transplant is accompanied by major risks, including Graft-versus-Host Disease (GVHD), severe infection, organ toxicity, and treatment-related death.

What HSCT Does and Does Not Fix

It is vital for families to understand that a transplant is a “blood and marrow cure,” not a “whole-body cure” ^[1].

• What it Fixes: A successful transplant provides a new immune system and stable blood counts, greatly reducing (though not fully eliminating) the risk of SDS-related leukemia ^[1].
• What it Does Not Fix: The genetic mutation remains in the rest of the body’s cells. This means your child will still likely have Exocrine Pancreatic Insufficiency (EPI) and will still need to undergo nutritional and enzyme review ^[1]. It also does not “fix” skeletal issues or neurodevelopmental challenges ^[1][7].
• Growth: In some cases, growth can actually slow down further after a transplant, meaning your child will still need close monitoring by an endocrinologist ^[8].

Supporting the Marrow: The Role of G-CSF

To help manage low white blood cell counts (neutropenia) before a transplant, doctors may use a medication called G-CSF (Granulocyte Colony-Stimulating Factor) ^[9].

• The Benefit: It “boosts” the marrow to produce more infection-fighting neutrophils ^[9].
• The Nuance: There has been historical concern that G-CSF might “push” the marrow to develop leukemia faster. However, observational research has not shown that G-CSF itself causes leukemia in SDS; the underlying biology drives the risk ^[10][11]. It can cause side effects like bone pain or an enlarged spleen.
• Management: While G-CSF is a helpful tool to prevent severe infections, the decision is individualized. Patients using G-CSF still require strict specialist monitoring ^[4][12].

A transplant is a path toward a more stable future for many children with SDS, but it requires a lifelong commitment to monitoring the systems that the transplant does not change. 🛡️ Working with an experienced transplant center that specializes in inherited marrow failure syndromes is the best way to navigate these choices.